PubRank

Maureen F Zakowski

Author PubWeight™ 158.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 25.93
2 Characterizing the cancer genome in lung adenocarcinoma. Nature 2007 16.48
3 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005 13.40
4 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006 6.91
5 Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013 6.10
6 Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006 5.69
7 Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011 4.16
8 Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006 4.06
9 Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013 3.64
10 The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011 3.41
11 Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009 3.14
12 Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012 2.85
13 EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006 2.83
14 Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008 2.68
15 Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011 2.58
16 Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008 2.56
17 Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012 2.52
18 EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013 2.43
19 Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One 2007 2.25
20 Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One 2007 2.14
21 Evidence-based pathology and the pathologic evaluation of thymomas: transcapsular invasion is not a significant prognostic feature. Arch Pathol Lab Med 2008 2.05
22 Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 2012 2.04
23 EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn 2008 1.99
24 Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2011 1.98
25 High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009 1.93
26 Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol 2011 1.67
27 Small-cell lung cancers in patients who never smoked cigarettes. J Thorac Oncol 2014 1.60
28 Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012 1.56
29 Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011 1.53
30 Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003 1.48
31 Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012 1.46
32 Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol 2010 1.45
33 Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006 1.44
34 Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009 1.42
35 Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 2011 1.34
36 Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002 1.21
37 Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 2010 1.19
38 Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 2010 1.08
39 Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011 1.07
40 Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol 2011 1.07
41 Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg 2010 1.04
42 Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol 2012 1.04
43 Pulmonary toxicity associated with erlotinib. Chest 2007 1.02
44 Cytology of desmoplastic small round cell tumor. Cancer 2002 1.00
45 Breast masses in males: multi-institutional experience on fine-needle aspiration. Diagn Cytopathol 2002 0.98
46 Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer 2012 0.98
47 Evidence-based pathology and the pathologic evaluation of thymomas: the World Health Organization classification can be simplified into only 3 categories other than thymic carcinoma. Cancer 2008 0.93
48 Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. Lung Cancer 2011 0.93
49 Pulmonary tumorlets: CT findings. AJR Am J Roentgenol 2004 0.92
50 Cytopathologic analysis of thyroid lesions in the pediatric population. Diagn Cytopathol 2006 0.90
51 Monophasic synovial sarcoma: a cytologic spectrum. Diagn Cytopathol 2004 0.89
52 The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003 0.86
53 Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003 0.83
54 Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010 0.82
55 SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma. Ann Thorac Surg 2004 0.82
56 Exfoliative sputum cytology of cancers metastatic to the lung. Diagn Cytopathol 2005 0.81
57 The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol 2013 0.80
58 Aspiration cytomorphology of fetal adenocarcinoma of the lung. Am J Clin Pathol 2010 0.77
59 Lung carcinoma in the era of personalized medicine: the role of cytology. Acta Cytol 2012 0.77
60 Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. Ann Thorac Surg 2008 0.76
61 Low interobserver agreement in cytology grading of mucinous pancreatic neoplasms. Cancer Cytopathol 2014 0.76
62 Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies. J Thorac Oncol 2010 0.75
63 Hodgkin's lymphoma associated with plasma cell neoplasia: cytological features and review of the literature. Diagn Cytopathol 2005 0.75
64 Comparison of multiplanar reformatted CT lung tumor measurements to axial tumor measurement alone: impact on maximal tumor dimension and T stage. AJR Am J Roentgenol 2013 0.75